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Exotoxin A is one of the virulence factors of Pseudomonas aeruginosa, a bacterium that can cause infections resulting in adverse
health outcomes and increased burden to health care systems. Current methods of diagnosing P. aeruginosa infections are time
consuming and can require significant preparation of patient samples. This study utilized a novel variation of the Systematic
Evolution of Ligand by Exponential Enrichment, Decoy-SELEX, to identify an Exotoxin A specific single-stranded DNA (ssDNA)
molecular recognition element (MRE). Its emphasis is on increasing stringency in directing binding toward free target of interest
and at the same time decreasing binding toward negative targets. A ssDNA MRE with specificity and affinity was identified after
fourteen rounds of Decoy-SELEX. Utilizing surface plasmon resonance measurements, the determined equilibrium dissociation
constant (𝐾𝑑) of the MRE is between 4.2 𝜇M and 4.5 𝜇M, and is highly selective for Exotoxin A over negative targets. A ssDNA
MRE modified sandwich enzyme-linked immunosorbent assay (ELISA) has been developed and achieved sensitive detection of
Exotoxin A at nanomolar concentrations in human serum. This study has demonstrated the proof-of-principle of using a ssDNA
MRE as a clinical diagnostic tool.
1. Introduction
Exotoxin A is a virulence factor secreted by Gram negative
bacilli bacteria,Pseudomonas aeruginosa [1].P. aeruginosahas
been identified as an opportunistic bacterium that is com-
monly associated with wound infections, nosocomial lung
infections, and respiratory diseases in cystic fibrosis patients
[2, 3]. Due to increasing antibiotic resistance, infections
caused by P. aeruginosa have been associated with decrease
in the quality of life, increased mortality in patients, and
significant cost burden in health care systems [4, 5].
Upon covalent cleavage of the full length protein, the
enzymatically active fragment of Exotoxin A enters host cells
[6]. It causes ADP-ribosylation of elongation factor 2 and
thus inhibits polypeptide assembly to ribosome and protein
translation, causing death of host cells [7, 8]. Early studies of
purified Exotoxin A report an intravenous lethal dose as low
as 3 𝜇g/kg in mice or a LD50 of ∼10 𝜇g/kg via intraperitoneal
injection [9, 10]. Because of this highly toxic nature, it is
essential to treat P. aeruginosa infection as early as possible.
However, current diagnosis of P. aeruginosa infection
largely relies on traditional methods, such as Gram-stain,
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bacterial culturing, biochemical methods, and immunoas-
says [11]. Though those methods are sensitive and reliable,
they require a significant amount of time to confirm infection,
prolonging the time between patient clinical presentations
and antibiotics treatments. This leads to the initial use of
nonspecific broad spectrum antibiotics and increases the
selection pressure for antibiotic resistant strains of the bac-
teria [12]. In recent years, molecular diagnostic techniques
have been developed to increase the efficiency of diagnosing
P. aeruginosa infection. A majority of these new techniques
use polymerase chain reaction (PCR) to identify genes in P.
aeruginosa [13–16]. Although PCR based diagnostic methods
are proven to be sensitive, clinical samples presented may
have DNA polymerase inhibitor and other contaminants
that increase chances of false positive, which means that
a greater amount of time is required to purify samples
[17]. Another major limitation of PCR is that it cannot
detect and monitor levels of virulence factors, such as
membrane antigens and toxins [17]. For example, gene code
for Exotoxin A production is not expressed constitutively,
due to different environmental factors [18, 19]. Previous
studies have demonstrated the clinical role of Exotoxin A
in the pathogenesis of P. aeruginosa infections [20]. Patients
with higher amount of antibodies against Exotoxin A were
correlated with better prognosis [21, 22]. This suggests that
Exotoxin A is a significant virulence factor of the bacteria and
is an important P. aeruginosa infection biomarker. However,
there is currently lack of regulatory approved Exotoxin A
detection methods for diagnosis purpose. Therefore, there
is an increasing need to develop new methods to rapidly
measure Exotoxin A through molecular recognition and
detection, therefore facilitating the diagnosis of P. aeruginosa
infections.
Systematic Evolution of Ligand by Exponential Enrich-
ment (SELEX) was first described by the Gold laboratory in
1990 [27]. It utilizes an in vitro selection process that identifies
Molecular Recognitions Elements (MREs) that have very
high affinity and specificity to their target molecules. The
selection process of nucleic acid MREs usually begins with a
library of 1013 to 1015 different single-strandedDNA (ssDNA)
or RNA molecules. The library is then subjected to repeating
cycles of partitioning and enrichment for molecules that
bind to positive target (target of interest) but not to negative
targets. Eventually a single MRE is identified with high
specificity and affinity to the target of interest that will be
useful for its detection.
In this study, a novel variation of SELEX termed Decoy-
SELEX has been utilized for the identification of a single-
stranded DNA MRE that binds to Exotoxin A with high
affinity and specificity. The advantage of this variation is an
increased emphasis on selecting against negative targets. The
first negative target, bovine serum albumin (BSA), is selected
based on the similarity in structure and amino acid sequence
to human serum albumin [28], which is an abundant protein
in blood samples. The second negative target, Cholera toxin,
served as example of common bacteria virulence factor [29].
The selection scheme is also designed to decrease nonspecific
binding to streptavidin and biotin, substrates used in target
Table 1: Decoy-SELEX scheme for Exotoxin A MRE selection.
Round Positive selection (+) Negative selection (−)
1 Immobilized target (IT)46 hrs, 50 𝜇L
Immobilization substrate
(IS) 18 hrs, 50 𝜇L
2 IT 24 hrs, 50𝜇L IS 22 hrs, 50𝜇L
3 IT 18 hrs, 50 𝜇L —
4 IT 12 hrs, 50 𝜇L IS 20 hrs, 50 𝜇L
5 IT 8 hrs, 50 𝜇L —
6 IT 5.5 hrs, 50 𝜇L BSA immobilized negativetarget (INT) 24 hrs, 50 𝜇L
7 IT 1 hrs, 50 𝜇L —
8 IT 1 hrs, 25 𝜇L Cholera toxin INT 18 hrs,50 𝜇L
9 IT 1 hrs, 5 𝜇L —
10 IT 5min, 5 𝜇L BSA INT 24 hrs, 50 𝜇L
11 IT 5 sec, 5 𝜇L IS 21 hrs, 10𝜇L
12 IT 5 sec, 5 𝜇L —
13
IT 5 sec, 5 𝜇L; competitive
elution with 2𝜇g free
Exotoxin A, 5 sec
IT 5 sec, 5 𝜇L; competitive
elution with 1mg/mL free
BSA, 5min
14
IT 5 sec, competitive
elution with 1 𝜇g free
Exotoxin A, 5 sec
—
In vitro selection performed for identifying ExotoxinA specificMRE. Immo-
bilized target (IT) is Exotoxin A bound to magnetic beads. Immobilization
substrate (IS) is streptavidin-coated magnetic beads blocked with biotin
regent. BSA is the abbreviation for bovine serum albumin. Times listed are
incubation times in hours (hrs), minutes (min), or seconds (sec).
immobilization. Surface plasmon resonance has been used to
characterize the affinity and specificity of the selected MRE.
In addition, amodified enzyme-linked immunosorbent assay
(ELISA) has been developed by using the selectedMRE as the
toxin capturing element in human serum and demonstrated
the potential use in clinical diagnosis [30–32].
2. Materials and Methods
2.1. Decoy-SELEX Method for Selection of Exotoxin A Specific
MREs. Asingle-strandedDNA (ssDNA) library consisting of
1015 molecules was used to begin the selection of Exotoxin
A specific MREs. This library, named RMW.N34, consisted
of two 23-base constant regions for primer annealing flanked
by a 34-base random region. It was designed by our labora-
tory and commercially synthesized (Eurofins MWGOperon;
Huntsville, AL, USA). A total of 14 rounds of Decoy-SELEX
were utilized to enrich Exotoxin A specific MREs (Table 1)
and eliminate MREs that bind to negative targets (Figures 1
and 2).
Exotoxin A in lyophilized powder form (List Biological
Laboratories; Campbell, CA, USA) was reconstituted in pure
water and then covalently biotinylated via Sulfo-NHS-LC-
Biotinylation (Pierce; Rockford, IL, USA) according tomanu-
facturer’s protocol. Biotinylated Exotoxin A was washed with
ZEBA Spin Desalting Column (Pierce, Rockford, IL, USA)
to remove excess unreacted biotin. Subsequently, biotinylated










Figure 1: Illustration of the Decoy-SELEX process. In vitro selection begins with incubation of target Exotoxin A with a library of 1015 ssDNA
molecules. Bindingmolecules are amplified and subjected to incubation withmultiple negative targets. Molecules that do not bind to negative
targets are amplified and carried on to the next round of selection.
ExotoxinAwas bound to streptavidin-coatedmagnetic beads
(New England Biolabs, Ipswich, MA, USA) and washed to
generate immobilized target (IT) for selections.
In round 1(+) of selection, 50 𝜇L of IT was incubated with
1015 copies of ssDNA from the library in a total of 500𝜇L
of selection buffer composed of 100mM sodium chloride,
20mM Tris-HCl, and 2mM magnesium chloride (1x selec-
tion buffer) at room temperature for 46 hours on rotisserie.
After the incubation, the selection mixture was subjected
to magnetic separation. Unbound ssDNA was removed and
ssDNA-bound to IT was washed with 500 𝜇L of selection
buffer three times and resuspended in 100 𝜇L of selection
buffer.This solution containing IT functioned as template for
PCR amplification using the following reaction conditions:
enriched ssDNA, 400 nM forward and biotinylated reverse
RMW.N34 primers (Eurofins MWGOperon; Huntsville, AL,
USA) (forward: 5󸀠-TGTACCGTCTGAGCGATTCGTAC-3󸀠,
biotinylated reverse: 5󸀠-Biotin-GCACTCCTTAACACTGAC-
TGGCT-3󸀠), 250 𝜇M deoxynucleotide triphosphates, 1x
GoTaq Reaction Buffer (Promega; Madison, WI, USA), 3.5
units of Taq, and pure water. Thermal cycling conditions
were as follows: first denaturing at 95∘C for 5 minutes;
cycling at 95∘C for 1 minute, 63∘C for 45 seconds, and 72∘C
for 1 minute; and final extension temperature at 72∘C for 7
minutes. Large-scale PCR (2 to 4mL) was performed after
each round of positive and negative selection.
After PCR amplification, PCR product containing
dsDNA was purified with the GFX PCR purification kit (GE
Healthcare, Piscataway, NJ, USA). Eluted dsDNA containing
the biotinylated reverse strand was then incubated with
streptavidin agarose resin (Pierce; Rockford, IL, USA) for
single strand separations [33]. This mixture was transferred
into a flow-through column and washed with 5 volumes of
1x phosphate buffer solution. Five volumes of 1M sodium
hydroxide were then added to the column to elute the
forward strand of the dsDNA. Subsequently, 0.1 volumes
of 3M sodium acetate at pH 5.2, 2.5 volumes of cold 100%
ethanol, and 10 𝜇g/mL of glycogen were added to the
eluted ssDNA for ethanol precipitation at −80∘C. After the
solution was frozen, it was then centrifuged at 13,000×g for 1
hour. Precipitated ssDNAwas subsequently washedwith 70%
ethanol and centrifuged at 13,000×g for 15minutes to remove
coprecipitated salt. The ssDNA pellet was dried in a vacuum
desiccator and resuspended in 50𝜇L of selection buffer. A
NanoDrop spectrometer (ThermoScientific; Wilmington,
DE, USA) was used to confirm that the suspension contained
at least 1013 copies of ssDNA before proceeding to next round
of selection.
Round 1(−) was performed by incubating enriched
ssDNA from the preceding positive round with immobiliza-
tion substrate in a total volume of 100𝜇L selection buffer at
room temperature for 18 hours on rotisserie. Immobilization
substrate was prepared by incubating Sulfo-NHS-LC-Biotin
(Pierce; Rockford, IL, USA) with Tris-HCl and streptavidin-
coated magnetic beads (New England Biolabs, Ipswich, MA,
USA). After magnetic separation, unbound ssDNA served
as the template for PCR amplification as illustrated above.
Positive rounds 1 to 7 and negative rounds 1, 2, 4, and 11 were
performed as described with decreasing incubation time in
positive rounds and increasing incubation time in negative
rounds to increase stringency for selection of MREs specific
for Exotoxin A.
Starting with round 6(−) of selection, the first negative
target, bovine serum albumin (BSA) (Rockland Immuno-
chemical; Gilbertsville, PA, USA), was introduced to the
selection. Immobilized negative targets (INT) were prepared
identical to IT, substituting Exotoxin A with bovine serum
albumin. INT, 50 𝜇L, was incubated with enriched ssDNA
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(a) Exotoxin A (b) Streptavidin








Figure 2: Structures of targets used in the Decoy-SELEX and SPR cross-binding assays. (a) Ribbon structure of the target of interest, Exotoxin
A (PDB 1IKQ, 66 kDa) [8]. (b) Ribbon structure of streptavidin (PDB 4GJS, 60 kDa) used in cross bind assays [23]. ((c), (d)) Ribbon structures
of bovine serum albumin (PDB 4F5S, 66.5 kDa) and Cholera toxin (PDB 2A5D, 84 kDa) used in negative rounds of selection and crossing
binding assays [24, 25]. (e) Chemical structure of biotin used in negative rounds of selection and cross-binding assays.
from the preceding positive selection round in a total of
500𝜇L of selection buffer at room temperature for 24 hours.
Unbound ssDNA was removed with magnetic separation
and served as template for PCR amplification. Round 10(−)
was performed in the same way. In round 8(−), the second
negative target, Cholera toxin (List Biological Laboratories;
Campbell, CA,USA), was introduced. Preparation of Cholera
toxin INT was as described above. Selection conditions
were similar to round 6(−) with the exception of 18-hour
incubation. This was to ensure that the selected MRE was
specific to Exotoxin A and not BSA or Cholera toxin.
Starting with round 8(+) of selection, the volume of IT
used was decreased in order to increase the stringency of
the selection. Rounds 13(+) and 14(+) of IT were subjected
to competitive elution with free Exotoxin A solution. IT and
the enriched ssDNA were initially incubated for 5 seconds
in total of 100𝜇L of selection buffer. IT with bound ssDNA
was washed with 500 𝜇L of selection buffer three times, then
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2 𝜇g or 1 𝜇g, respectively, of Exotoxin A in 100𝜇L of selection
buffer was added to the mixture and then incubated for 5
seconds.The supernatant obtained frommagnetic separation
was used as template for PCR amplification. Round 13(−) was
performed in the same way using a free BSA competitive
elution; however, ssDNA bound to IT was separated and
served as PCR template.This was to ensure ssDNAonly binds
to free Exotoxin A and not to free negative targets.
2.2. Cloning and Sequencing of Exotoxin A Specific MREs.
DNA sequencingwas performed following rounds 3(+), 6(−),
9(+), 12(+), 13(+), and 14(+) to analyze the ssDNA library
for consensus binding sequences. The ssDNA library was
amplified with nonbiotinylated primers. It was then ligated
into the pCRII vector (Invitrogen, Carlsbad, CA, USA) and
transformed into competent E. coli bacteria according to
manufacturer’s protocol. Inserted plasmid was subsequently
extracted and purified with the AxyPrep Plasmid Miniprep
Kit (Axygen, Union City, CA, USA). The M13R primer,
complementary to a region upstream of the PCR insert, was
sequenced (Eurofins MWG Operon, Huntsville, AL, USA)
along with purified plasmid. A total of 30–50 randomly
selected sequences for each respective round were subjected
to analysis for consensus sequence families [34, 35].
2.3. Exotoxin A MRE Binding Assays with Surface Plasmon
Resonance. After analyzing round 14 for its DNA sequences,
R14.33 was selected for further characterization. The Mfold
DNA web server was used to predict the secondary structure
with the following conditions: 25∘C, 100mMNa+, and 2mM
Mg2+ [26]. Subsequently, R14.33 was synthesized by Eurofins
MWG Operon with a 5󸀠 amino-C6 modification for use in
surface plasmon resonance (SPR) binding assays.
Glass slides (12mm × 10mm) were cleaned by sonication
in acetone, isopropyl alcohol, and doubly deionized water
(5min, each) and then blown dry with nitrogen. Gold was
evaporated onto the slides using Temescal BJD-2000 system
(Edwards Vacuum; Phoenix, AZ, USA) with an Inficon
XTC/2 deposition controller (Inficon; East Syracuse, NY,
USA) (chamber pressures ≤ 1.0 × 10−6 Torr). Samples were
rotated (3 rpm) and monitored during deposition for metal
thickness (6MHz quartz piezoelectric crystals, gold-coated)
(Kurt J. Lesker Co., Clairton, PA, USA). Rates of 0.3−0.5 Å/s
were maintained during the deposition of a titanium adhe-
sion layer (2 nm) and a gold layer (50 nm). After that, samples
were cooled to room temperature before being removed from
the chamber.
The gold slide was then cleaned in 100% ethanol under
sonication for 5 minutes and then placed in a solution
containing 10mM 11-mercaptoundecanoic acid (11-MUA)
(Sigma; St. Louis, MO, USA) and 10mM triethylene glycol
mono-11-mercaptoundecylether (PEG3) (Sigma; St. Louis,
MO, USA) in a 1 to 5 ratio for 24 hours under argon. After
the formation of the self-assembled monolayer (SAM), the
gold slide was rinsed with 100% ethanol, pure water, and
blown dry with a slow stream of nitrogen. The prepared
gold slide was inserted into the carrying cartridge and
docked into a Biacore X100 (GE Healthcare; Piscataway, NJ,
USA). The running buffer for immobilization was composed
of 100mM sodium chloride, 20mM potassium phosphate,
and 2mM magnesium chloride, pH 7.56 (1x immobiliza-
tion buffer). Next, 100mM N-hydroxysulfonyl succinimide
(sulfo-NHS) (Pierce; Rockford, IL, USA) and 400mM 1-
ethyl-3-(3-dimethylaminopropyl) (EDC) (Pierce; Rockford,
IL, USA) were mixed (1 : 1) and injected into flow cell 1 and 2
at a flow rate of 5 𝜇L/min for ten minutes for the activation of
the carboxyl group of 11-MUA.Then, 300 𝜇L of 1 𝜇M5󸀠 amino
modified ssDNA in immobilization buffer (after denaturing
at 95∘C for 5min and cooling to room temperature) was
injected into flow cell 2 at a rate of 5 𝜇L/min. At the end of the
DNA injection, unreacted carboxyl groups were inactivated
by injection of selection buffer twice for a total of twenty
minutes, followed by a regeneration cycle with 45mMglycine
and 100mM sodium hydroxide in 5% ethanol (regeneration
buffer) for 30 seconds [36, 37].
After immobilization, selection buffer was then used as
the running buffer for binding assays. The binding affinity of
R14.33 was determined by injecting concentrations of 0, 0.5,
1, 1.2, 1.4, and 2𝜇Mof Exotoxin A in flow cells 1 and 2 at a flow
rate of 5 𝜇L/min at room temperature. Each cycle comprised
a 180-second wait period, 180-second contact period, 180-
second wait period, and 30-second regeneration period using
regeneration buffer. Assays were performed in duplicate [36,
37]. Kinetic data was analyzed using the Scrubber-2 software
(BioLogic Software; Campbell, Australia) to determine the
equilibrium dissociation constant (𝐾𝑑), assuming a one-to-
one kinetics model.
To determine the cross-binding activity of R14.33 to nega-
tive targets, blank selection buffer and 5𝜇M each of Exotoxin
A, BSA, biotin (Sigma; St. Louis, MO, USA), Cholera toxin,
and streptavidin (Amresco; Solon, OH, USA) were injected
into both flow cells with the same conditions as described
above. Each molecule was tested in triplicate. All data was
averaged and standard deviations were calculated as previ-
ously described [36]. One-way ANOVA and Bonferroni post
hoc test were performed to determine statistical differences
in the means for analytes.
2.4. Exotoxin A MRE Modified ELISA Assays. A sandwich
ELISA assay modified with ssDNA MRE was developed.
R14.33 was commercially synthesized with 5󸀠 biotinylation
for the use as the antigen capturing element (Eurofins MWG
Operon; Huntsville, AL, USA). Streptavidin-coated 96-well
plate (Pierce; Rockford, IL, USA) was washed three times for
5 minutes, with 200𝜇L of wash buffer (1x selection buffer,
0.1% BSA, 0.05% Tween-20 detergent). Subsequently, 100𝜇L
of 40 nM 5󸀠 biotinylated ssDNA in selection buffer (after
denaturing at 95∘C for 5min and cooling to room tempera-
ture) was added to sample wells and incubated for 2 hours
with shaking at room temperature. Each well was washed
three times with wash buffer to remove nonimmobilized
ssDNA. A negative control for each replicate consisted of
a blank well without immobilized ssDNA. Then, 100 𝜇L of
each 1x phosphate buffer solution, selection buffer, 100 nM
of Exotoxin A in selection buffer, human serum (Sigma; St.
Louis, MO, USA), or 100 nM of Exotoxin A in human serum
was added to individual samplewells.Theplatewas incubated
for 1 hour with shaking at room temperature.
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Following sample incubation, each well was washed
three times with wash buffer to remove unbound Exotoxin
A. Next, 100 𝜇L of 1 : 100 dilution of primary goat anti-
Exotoxin A antibody (List Biological Laboratories; Campbell,
CA, USA) in wash buffer was added to each well and
followed by 30 minutes of incubation with shaking at room
temperature. Following primary antibody incubation, each
well was washed three times. Subsequently, 100𝜇L of 1 : 500
dilution of secondary rabbit anti-goat antibody conjugated
to horseradish peroxidase (Pierce; Rockford, IL, USA) in
wash buffer was added to each well and incubated for 30
minutes at room temperature with shaking. Lastly, each
well was washed five times to remove nonspecifically bound
antibodies. Controls without antibodies and with only pri-
mary antibodies added were also performed. Assays were
performed in quadruplicate.
ABTS substrate (Pierce; Rockford, IL, USA) was added to
each well according to the manufacturer’s instruction. After
ABTS was added, absorbance was measured in a Synergy 2
microplate reader with OD reading at 410 nm and 650 nm
using Gen5 1.06 software (Biotek US; Winooski, VT, USA) in
two-minute increments. All data was averaged and standard
deviations were calculated. For each Exotoxin A containing
sample, a two-tailed Student’s 𝑡-test was performed to deter-
mine statistical differences, respectively, to selection buffer or
human serum blank controls at 𝑃 < 0.05.
3. Results and Discussions
3.1. Selection of Exotoxin A Specific MREs. Fourteen rounds
of Decoy-SELEX were performed to identify ssDNA MREs
specific to Exotoxin A (Table 1). The selection scheme was
aimed to direct the ssDNA MREs to bind to free Exotoxin A
in solution and reduce enrichment of nonspecific binding to
immobilization substrates, BSA, and Cholera toxin. Initially,
30–50 randomly selected sequences were analyzed for the
presence of consensus sequence families after rounds 3, 6, 9,
and 12. Toward the end of the selection, in order to monitor
the convergence of families more frequently, 30–50 random
sequences from both rounds 13 and 14 were analyzed as
previously described [34, 35, 38].
In the round 14 of ssDNA library, there was a noticeable
and significant presence of sequence families in one sequence,
R14.33 (Table 2). This sequence appeared in about 40% of
the sequence families. R14.33 had one possible predicted
structure, with a relatively low Gibbs free energy value
of −9.93 kcal/mol according to the Mfold prediction. This
indicated a relatively stable secondary structure at the given
conditions (Figure 3). The variable region of R14.33 also par-
ticipated in the formation of two stem-loop structures [39].
Therefore, R14.33 was chosen for further characterization.
3.2. Affinity and Specificity of Exotoxin A Specific MRE.
Affinity of the selected MRE was determined by SPR binding
assays. Assays were performed with Exotoxin A concentra-
tion from high nM to low 𝜇M range with at least 2 duplicate
concentrations. The equilibrium dissociation constant (𝐾𝑑)
was between 4.2 and 4.5 𝜇M (Figure 4). In recent years,
there have been a number of MREs selected against protein
targets which utilized SPR for characterization of binding
affinity. Reported equilibrium dissociation constants in these
studies range from low-nanomolar to high-nanomolar [40–
44]. It is to be noted that these studies relied on different
immobilization methods compared to what was used here,
including streptavidin-biotin linkage and thiolated DNA
attachment [41–44]. Also, several studies utilized a sandwich
detectionmethod to amplify signals, thus enhancing the limit
of detection [42, 45, 46].
SPR cross-binding assays were performed to test the
specificity of the selected Exotoxin A MRE. Concentrations
of all cross-binding analytes were higher than those used
in affinity assays to ensure that R14.33 has no nonspecific
binding to negative targets.Themethod of presentation of the
current data as relative response unit of R14.33 to all analytes
has been previously described [36, 46]. Binding responses
showed a much higher affinity of R14.33 to Exotoxin A in
solution than to all negative targets (one-wayANOVA:𝐹2,12 =
573.4, 𝑃 < 0.001) (Figure 5), and to streptavidin, a significant
component of the immobilization substrate. This is notewor-
thy as streptavidin was present in all of the selection rounds.
It is clear that competitive elutions performed in the last two
positive rounds gave the ssDNA library selectivity for free
Exotoxin A in solution over immobilized target and other
negative targets, thus validating the Decoy-SELEX method.
The determined equilibrium binding constant of the
selected Exotoxin A MRE is higher than other studies
utilizing SPR binding assays. This difference is likely due to
different methods of immobilizing the ssDNAMRE as noted
above and thus leads to a lower level of immobilization and
detection responses.The current study utilizes direct covalent
conjugation of 5󸀠 amino modified ssDNA to the SAM
on gold surface [34, 35, 37]. However, covalently attached
DNA provides a more stable immobilization as compared to
streptavidin/biotin and thiolated DNA attachment under a
wide range of storage conditions.This is a potential advantage
in the real application of a ssDNA MREs based biosensor, as
the longevity of the biological probe is a huge determining
factor of its application value [47]. It is also important to
note that previous study demonstrated a 100-fold higher
𝐾𝑑 between SPR binding measurements and binding assays
relying on free ssDNA in solution [48]. This is likely due to
the difference in the availability of binding pockets on MREs
that are immobilized on solid platform as compared to being
in solution.The SPR setup in this study is also very similar to
the potential design of a final sensor. Therefore, this is a very
realistic assay and is translational as a sensor.
3.3. Diagnostic Application of Exotoxin A Specific MRE. The
Exotoxin A specific MRE demonstrated high specificity and
minimal cross-binding activity to BSA. It is reasonable to
believe that this low binding property may be extrapolated
to human serum albumin [41].This allowed the investigation
of using the selected MRE as a potential diagnostic tool. A
sandwich ELISA assay modified with the ssDNAMRE as the
toxin capturing element was developed. Reproducible and
statistically significant detection of Exotoxin A at 100 nM
in spiked human serum samples was achieved compared to
negative controls in six independent assays (𝑃 < 0.05 to















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Secondary structure and sequence of R14.33 ssDNA MRE. (a) ssDNA sequence of Exotoxin A MRE R14.33. Gray letters indicate












































































Figure 4: SPR binding kinetics assays of R14.33. Data represent 𝐾𝑑 of R14.33 from two binding assays evaluated via Scrubber 2 software
(Software; Campbell, Australia). (a) Representative binding response curve of R14.33. (b) Equilibrium dissociation constants and standard
error of two binding assays.


























Figure 5: SPR cross-binding assays of R14.33. Data represent
specificity of R14.33 Exotoxin AMRE. Error bars represent standard
deviations of three runs. Statistical significance levels of 𝑃 < 0.001
are designated by “∗”. The observed significance levels are adjusted
by Bonferroni post hoc procedure. Exotoxin A has a significantly
higher response when compared to blank control and all other
analytes, indicating low cross-binding activities of R14.33. Blank
represents 1x selection buffer. Concentrations of all analytes are at
5 𝜇M.
𝑃 < 0.001) (Figure 6). It has been reported that ssDNA
MRE generally has a half-life of 1 hour in human serum
due to the presence of exonuclease [49]. Therefore, toxin
incubation time that ranged from five minutes to one hour
was tested during assay development. While a portion of
the immobilized MRE is likely to be degraded in serum
condition, the one-hour toxin incubation period yielded the
most consistent result and therefore it was utilized in all
experimental assays.
Previous study has attempted to incorporate ssDNAMRE
into a system for target detection in buffer diluted human
serum [50]. Similar ssDNA MRE modified ELISA assay
for the detection of bacteria toxins has been previously
described [51, 52]. However, clinically relevant samples were
not tested in both studies. It is known that the binding
activities of nucleic acid MREs are highly dependent on their
three-dimensional structures and are influenced by factors
such as temperature, pH, and ionic strength of the binding
environment [39].This leads to challenges in applying nucleic
acid MREs in targets’ native complex environments, such as
human serum [53].This study demonstrated an improvement
to these previous reported studies by showing the robustness
of the selected Exotoxin A specific MRE in undiluted serum
without any base modifications, and it was able to retain a
level of binding activity in an environment that was very
much different compared to the selection condition.
Currently, there are limited studies in quantifying the
amount of Exotoxin A in vivo. Previous studies showed large
differences in the levels of Exotoxin A detected in murine
serum (averaged 116.0 ng/mL) and in culturemedia (averaged
1.4 𝜇g/mL) [54, 55]. One study showed significant differences
in Exotoxin A detected in different patient sputum samples
(0.3 ng/mL to 126 ng/mL), and as high as 29.3 𝜇g/mL of
ExotoxinAwas detected in the culture supernatant of sputum
isolated P. aeruginosa [56]. It has also been reported that
blood isolated P. aeruginosa produced the highest amount of
Exotoxin A in culture conditions (approximately 0.3 𝜇g/mL)
[57]. Overall, these results suggest that in vivo levels of
Exotoxin A vary significantly and are not well quantified in
human patients.
Historically, an ADP-ribosylation assay has been utilized
to quantify the amount of Exotoxin A in research studies [20,
57–60]. This assay requires the use of radioactive NAD and
extensive experimental preparations, and therefore it may
not be practical for diagnostic use. Although a traditional
antibody-based sandwich ELISA assay (MyBioSource; San
Diego, CA, USA) is commercially available with a reported
detection range between 0.156 ng/mL and 10 ng/mL, it was
designed for research purposes only. Also, the ranges of
Exotoxin A levels in vivo are likely to be wide. The relatively
narrow detection range of the commercial ELISA kit may
limit its usage in clinical samples. It is to be noted that, in our
ssDNA MRE modified ELISA assays, 100 nM or 6.6 𝜇g/mL
of Exotoxin A in human serum was detected. While this
is highly reproducible, the differences compared to negative
controls are small enough to be near the assay’s detection
limit. Based upon the available clinical data on Exotoxin
A level in patients, it is difficult to completely rule out the
clinical usage of the current ssDNA MRE modified ELISA
assay. In order to transition the current assay into a final
product for clinical use, it will likely require modification,
optimization, and possibly an industrial partnership for
development.Nevertheless, ssDNAMREmodified assay does
offer several advantages when compared to ELISA assays that
are based solely on antibodies, such as thermostability, and
regeneration of assay by a basic buffer wash [61].
Overall, this study has identified a ssDNA MRE with
high affinity and specificity for Exotoxin A of P. aeruginosa.
To the best of our knowledge, this is the first ssDNA MRE
targeting Exotoxin A. The successful use of SPR for MRE
characterizations showed the potential of it being incorpo-
rated into a SPR-based biosensor for real time, label-free
detection of Exotoxin A in biological matrices [41, 42]. In
addition, the ssDNA MRE modified ELISA assay offers a
potential new way to facilitate the diagnosis of P. aeruginosa
infection by rapidly identifying the presence of one of
the most significant virulence factors. The ELISA requires
minimal sample manipulations and approximately two hours
from toxin incubation to detection. This method may also
supplement direct diagnosis methods based on detecting the
presence of bacterial cells through culturing and PCR.
4. Conclusions
This study utilized a novel variation of the SELEX process,
Decoy-SELEX, to obtain a ssDNA Molecular Recognition











































Figure 6: Modified ELISA assays of Exotoxin A. Data represent one modified sandwich ELISA with absorbance measured at OD 410 nm.
Absorbance levels presented are subtracted from background levels of blank well without immobilized DNA. Error bars represent standard
deviations of 4 sample replicates in one independent assay. (a) Statistical significance levels with respect to buffer background of 𝑃 < 0.001
are designated by “∗”. (b) Statistical significant levels with respect to human serum background of 𝑃 < 0.001 are designated by “∗”. Buffer:
1x selection buffer; serum: human serum.
Element specific for Exotoxin A, a virulence factor of
Pseudomonas aeruginosa. The MRE is characterized to have
high affinity and specificity to its target, thus validating
the Decoy-SELEX methodology. It also showed sensitive
detection of Exotoxin A at nanomolar concentrations in
human serum through amodified sandwich ELISA assay and
demonstrated the proof-of-principle diagnostic application
of ssDNAMREs.
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